Researcher
Marc Ferrante
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Feb 2004 → Today
Projects
11 - 16 of 16
- Predicting outcomes of inflammatory bowel diseases: creating opportunities for personalized medicineFrom1 Oct 2015 → 30 Sep 2019Funding: FWO fellowships
- The role of intestinal microbiota in the development of inflammatory bowel diseases: identification of potential beneficial and harmful microbiota through ex vivo organoid technology.From1 Oct 2014 → 30 Sep 2016Funding: BOF - Other initiatives
- The role of intestinal microbiota in the development of inflammatory bowel diseases: identification of potentially beneficial and harmful micorbiota through ex vivo organoid technology.From1 Oct 2014 → TodayFunding: FWO fellowships
- Influence of microbiota on intestinal stem cell behaviour and differtiation in patients with inflammatory bowel diseases.From1 Oct 2012 → 30 Sep 2015Funding: BOF - Doctoral projects
- Influence of microbiota on intestinal stem cell behaviour and differentiation in inflammatory bowel diseases.From1 Sep 2012 → 30 Sep 2017Funding: FWO fellowships
- Influence of microbiota on intestinal stem cell behavior, differentiation and migration in patients with inflammatory bowel disease.From1 Oct 2010 → 30 Sep 2013Funding: FWO fellowships
Publications
1 - 10 of 476
- Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply.(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1007 - 1008 - Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.(2024)
Authors: Marc Ferrante
Pages: 121 - Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial(2024)
Authors: Marc Ferrante
Pages: 416 - 423 - Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 723 - 724 - Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.(2024)
Authors: Bram Verstockt, Marc Ferrante, João Guedelha Sabino, Jeroen Raes, Séverine Vermeire
Pages: 483 - 495 - IDH1-mutated Crohn's disease-associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated-type dysplasia.(2024)
Authors: Gert De Hertogh, Marc Ferrante
Pages: 515 - 524 - Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study(2024)
Authors: Dahham Alsoud, João Guedelha Sabino, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
- Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study(2024)
Authors: Jo Swinnen, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
- The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1 - 7 - SCFAs switch stem cell fate through HDAC inhibition to improve barrier integrity in 3D intestinal organoids from patients with obesity(2023)
Authors: Mona Farhadipour, Kaline Arnauts, Mathias Clarysse, Bart Van Der Schueren, Laurens Ceulemans, Ellen Deleus, Matthias Lannoo, Marc Ferrante, Inge Depoortere
Patents
1 - 5 of 5
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)